GlobeNewswire by notified

Acron Group’s Output Up 6% in 2021

Share

19 January 2022

Acron Group’s Output Up 6% in 2021

The Group’s Consolidated Output

(including operating results for Acron, Dorogobuzh,

and North-Western Phosphorous Company)

Product, ‘000 t20212020YOY, %
MINERAL FERTILISERS
Ammonia2,9092,7296.6%
Incl. in-house consumption2,8452,617
Nitrogen fertilisers, including5,0584,7077.5%
Incl. in-house consumption921690
AN2,2412,430-7.8%
Incl. in-house consumption339213
Urea1,4631,18023.9%
Incl. in-house consumption582477
Incl. prilled urea400485-17.5%
Incl. in-house consumption1716
Incl. granulated urea529261102.7%
Incl. in-house consumption3226
UAN1,3541,09623.5%
Complex fertilisers, including2,6252,37210.7%
Incl. in-house consumption6152
NPK2,4062,2367.6%
Incl. in-house consumption6152
Bulk blends21913661.0%
Total commercial output for Mineral Fertilisers6,7656,4484.9%
INDUSTRIAL PRODUCTS
Organic compounds, including47442312.1%
Incl. in-house consumption246213
Methanol105987.7%
Incl. in-house consumption9178
Formalin16915112.4%
Incl. in-house consumption150131
Urea-formaldehyde resins19917414.3%
Incl. in-house consumption64
Non-organic compounds, including:1,1871,03514.6%
Low-density and technical-grade AN46931847.5%
Industrial urea17014022.1%
Calcium carbonate483515-6.3%
Liquid carbon dioxide57553.1%
Argon77-2.3%
Total commercial output for Industrial Products1,4151,24513.6%
RAW PHOSPHATES
Apatite concentrate1,2551,1826.1%
Incl. in-house consumption950900
Total commercial output for Apatite Concentrate3052837.9%
TOTAL COMMERCIAL OUTPUT8,4857,9766.4%

Note:

Commercial output is output less in-house consumption.

Chairman of Acron’s Board of Directors Alexander Popov commented on the results:

‘Acron Group set a new record in 2021, ramping up commercial output 6% year-on-year to 8.5 million tonnes and outstripping the target set a year ago. As a key milestone in 2021 we can name completed Urea-6+ project that brought urea output to record 1.6 million tonnes.

‘Looking forward, we want to use the upward momentum of mineral fertiliser prices in 2021 and both accelerate ongoing investment projects and kick off new ones.

‘Upgrades to ammonia units 2 and 3 and urea units 1 through 4 are underway at Acron’s Novgorod-based site. We plan to complete these projects in 2023, which will boost ammonia capacity by 375 ktpa and urea capacity by 390 ktpa. At the same time, we will construct a second urea granulation unit.

‘In 2022, we plan to complete construction of a 100-ktpa calcium nitrate unit. We are undertaking production of this new water-soluble fertiliser in response to client demand around the world.

‘The Dorogobuzh site will see technical upgrades at its ammonia unit and the completion of a new nitric acid unit, which will result in a higher ammonium nitrate output and allow us to increase supplies to the domestic market, where this nitrogen fertiliser is traditionally popular.

‘We expect the Group’s commercial output to reach 8.7 million tonnes in 2022’.

Performance Analysis

In 2021, Acron Group’s total commercial output was up 6% to 8,485,000 tonnes. This increase was mainly due to a number of investment projects implemented at the Group’s Novgorod-based site in the recent years, including construction of a urea granulation unit in mid-2020, a capacity increase at the Ammonia-4 unit in late 2020, and a comprehensive overhaul of the Urea-6 unit in 2021. These efforts boosted output of nitrogen mineral fertilisers, industrial urea, and ammonium nitrate.

The Group’s mineral fertiliser output was up 5% to 6,765,000 tonnes last year. Industrial product output increased 14% to 1,415,000 tonnes following the Group’s success at promoting industrial-grade urea and ammonium nitrate in international markets. Output of these products was up 40% to 640,000 tonnes.

In 2021, the Group’s ammonia output was up 7% to 2,909,000 tonnes, and the volume of ammonia processed through to end products increased to 98% from 96%.

As production of industrial-grade ammonium nitrate went up last year, the Group saw an 8% dip in output of agricultural-grade ammonium nitrate to 2,241,000 tonnes. Output of agricultural-grade urea, however, was up 24% to 1,463,000 tonnes. The Group launched production of granulated urea in 2020 and doubled its output in 2021 year-on-year to 529,000 tonnes. UAN output was up 24% year-on-year to 1,354,000 tonnes due to a better price environment.

The Group’s output of complex fertilisers was up 11% in 2021 to 2,625,000 tonnes, backed by both a favourable price environment and increased production of apatite concentrate at the Oleniy Ruchey mine, where output was up 6% to 1,255,000 tonnes.

Market Trends

Global urea prices soared in Q4 2021. FOB Baltic Sea prices reached an all-time record high of USD 900 per tonne after a significant jump in natural gas prices with associated shutdowns of some capacity in Europe and export restrictions in China, Egypt, and Russia. Prices were further supported by strong demand from India and Brazil and high demand for urea in the industrial sector. In January 2022, urea prices adjusted as the import season came to a close in India and Brazil. That said, prices continue to be supported by high gas prices in Europe and export restrictions in China, Russia, and Egypt.

Like urea, ammonium nitrate and UAN prices increased rapidly in Q4 2021. FOB Baltic Sea prices set new records (USD 750 and USD 630 per tonne of AN and UAN respectively) backed by higher urea prices, which serve as a benchmark for these fertilisers, and higher production costs for these products in Europe resulting from soaring gas prices. Despite these issues, Russian producers continue to meet their commitments to support the domestic market and supply fertilisers to Russian growers at prices far below the global market.

NPK prices were on the rise in Q4 2021, driven mainly by higher prices for the basic products (urea, DAP, and potassium chloride). The increase in basic product prices outstripped blends because of their higher liquidity, so NPK 16-16-16 sold at a 5% discount to the basic product basket despite its historical average premium of about 20%. The premium over the basic products is expected to return to normal in the coming months.

Average Indicative Prices, USD/t, FOB Baltic/Black Sea

Q4 2021Q3 2021Q4 2020Q4 2021 /
Q3 2021

change
Q4 2021 /
Q4 2020

change
NPK 16-16-1657942526236.2%121.0%
AN646309166109.1%289.2%
UAN61230811998.7%414.3%
Urea80744523481.3%244.9%
Ammonia82257121144.0%289.6%


202120202021/2020
NPK 16-16-1641625662.5%
AN355167112.6%
UAN356125184.8%
Urea480222116.2%
Ammonia543204166.2%

Media contacts:

Sergey Dorofeev

Anastasia Gromova

Tatiana Smirnova

Public Relations

Phone: +7 (495) 777-08-65 (ext. 5196)

Investor contacts:

Ilya Popov

Investor Relations

Phone: +7 (495) 745-77-45 (ext. 5252)

Background Information

Acron Group is a leading vertically integrated mineral fertiliser producer in Russia and globally, with chemical production facilities in Veliky Novgorod (Acron) and Smolensk region (Dorogobuzh). The Group owns and operates a phosphate mine in Murmansk region (North-Western Phosphorous Company, NWPC) and is implementing a potash development project in Perm Krai (Verkhnekamsk Potash Company, VPC). It owns transportation and logistics infrastructure, including three Baltic seaport terminals and distribution networks in Russia and China. Acron subsidiary North Atlantic Potash Inc. (NAP) holds mining leases and an exploration permit for ten parcels of the potassium salt deposit at Prairie Evaporite, Saskatchewan, Canada. Acron also holds a minority stake (19.8%) in Polish Grupa Azoty S.A., one of the largest chemical producers in Europe.

In 2020, the Group sold 7.8 million tonnes of its main products to 74 countries, with Russia, Brazil, Europe, and the United States as key markets.

In 2020, the Group posted consolidated IFRS revenue of RUB 119,864 million (USD 1,661 million), with EBITDA of RUB 35,311 million (USD 489 million). Acron’s shares are traded on the Moscow Exchange, and its global depositary receipts are traded at the London Stock Exchange (ticker AKRN). Acron employs over 11,000 people.r

For more information about Acron Group, please visit www.acron.ru/en.

To view this piece of content from www.globenewswire.com, please give your consent at the top of this page.
To view this piece of content from ml-eu.globenewswire.com, please give your consent at the top of this page.

About GlobeNewswire by notified

GlobeNewswire by notified
GlobeNewswire by notified
One Liberty Plaza - 165 Broadway
NY 10006 New York

https://notified.com

GlobeNewswire by notified is one of the world's largest newswire distribution networks, specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media, investment community, individual investors and the general public.

Subscribe to releases from GlobeNewswire by notified

Subscribe to all the latest releases from GlobeNewswire by notified by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from GlobeNewswire by notified

Nextensa NV/SA : Shares repurchase26.5.2022 17:40:00 CEST | Press release

PRESS RELEASE REGULATED INFORMATION Brussels, 26 May 2022 – 5.40 PM CEST Nextensa NV/SA : Shares repurchase In accordance with article 8:4 of the Royal Decree of 29 April 2019 in execution of the Belgian Code of Companies and Associations, Nextensa announces that in the period between May 19, 2022 and May 25, 2022 included it has repurchased 1,889 treasury shares on Euronext Brussels as part of its announced share buy-back program1. The shares were repurchased at an average price (rounded) of € 68.00 per share. This share repurchase transaction was carried out to cover the purchase plans for the benefit of the executive management of Nextensa, and this within the limits set down in the (renewed) share repurchase authorization as granted by the extraordinary general meeting of shareholders on 19 July 2021. Detailed operations per day DateNumber of sharesAverage price (€)Minimum price (€)Maximum price (€)Total price (€)19/05/202245067.8667.7067.9030,535.0020/05/202245068.4868.4068.9030,8

Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons26.5.2022 15:00:33 CEST | Press release

26 May 2022 VOLTA FINANCE LIMITED (VTA / VTAS) Notification of Transactions of Directors/Persons Discharging Managerial Responsibility and Connected Persons On 24 May 2022, Mr Paul Meader, Director and Chairman of the Board of the Company, transferred 3,130 shares in the Company to his wife, Sarah Kingwell. Following this transaction the total interests in the Company of Mr Meader (and his Closely Associated Persons) remain unchanged at 48,175 shares, representing 0.13% of the issued shares in the Company. The below notification, made in accordance with the requirements of article 19.3 of the EU Market Abuse Regulation, gives further details: 1 Details of the person discharging managerial responsibilities / person closely associated a) Name 1) Paul Meader 2) Sarah Kingwell 2 Reason for the notification a) Position/status 1) Director and Chairman 2) PCA b) Initial notification /Amendment Initial Notification 3 Details of the issuer, emission allowance market participant, auction platfor

Mandalay Resources Corporation tillkännager resultatet av årsstämman26.5.2022 14:41:34 CEST | Pressemelding

TORONTO, May 26, 2022 (GLOBE NEWSWIRE) -- Mandalay Resources Corporation (”Mandalay” eller ”bolaget”) (TSX: MND, OTCQB: MNDJF) har nöjet att tillkännage resultaten från årsstämman (”mötet”) som hölls virtuellt idag. Alla resolutioner som presenterades vid mötet godkändes av aktieägarna och röstningen som skedde genom fullmakt motsvarade 67,63 % av de totalt utestående aktierna på avstämningsdagen. Val av styrelseledamöter Antalet styrelseledamöter var oförändrat med sju ledamöter och var och en av de sju nominerade som fanns listade i bolagsledningens informationsutskick från den 14 april 2022 återvaldes till bolagsstyrelsen. Abraham Jonker fortsätter som oberoende samordnande ledamot och Bradford Mills fortsätter som ordförande. Resultaten av rösterna genom ombud anges nedan. ResolutionVotes Cast by Proxy For% ForVotes Cast by Proxy Withheld% WithheldBradford A. Mills61,552,12099.95329,1930.047Abraham Jonker61,551,31399.95130,0000.049Amy Freedman61,547,53899.94533,7750.055Dominic Duff

Interim results for the period ended March 31, 202226.5.2022 13:30:47 CEST | Press release

Golar LNG Limited ("Golar" or "the Company") reports Q1 2022 ("Q1") Net income of $345.2 million.Adjusted EBITDA1 of $93.4 million for the quarter inclusive of FLNG Hilli, Golar Arctic and Golar Tundra but excluding the 8 TFDE vessels and management companies sold to Cool Company Ltd. ("CoolCo"). Sold 6.2 million New Fortress Energy Inc. ("NFE") shares in Q2 2022 ("Q2") realizing net cash proceeds of $253 million. Golar now owns 12.4 millionNFE shares following the sale.Q1 Total Golar Cash and Listed Securities1 position increased by $0.4 billion to $1.3 billion. Golar's share of Contractual Debt1 decreased by $0.5 billion to $1.7 billion in Q1 and a further $0.5 billion in Q2 after sale of remaining carriers to CoolCo in April.Agreed to sell the steam turbine carrier Golar Arctic as a converted FSRU to Italy's Snam for 269 million Euros ($288 million). Strong progress made on opportunities for FSRU Golar Tundra and on pipeline of FLNG projects. Shipping spin-off: A key focus for Q1 wa

Dante Labs highlights advancements to its drug discovery development program, demonstrating the value of genomic data to drug discovery26.5.2022 13:30:00 CEST | Press release

– Company announces rebranding to Dante Genomics to reflect its broader global efforts – NEW YORK, May 26, 2022 (GLOBE NEWSWIRE) -- Dante Genomics, a global leader in genomics and precision medicine, highlights significant progress made in its drug discovery development program with six drug candidates currently in the Company’s pipeline, applying Dante’s internal siRNA and mRNA technology to rare and common diseases. Since the company’s foundation, Dante has invested in a robust R&D program with the goal to create end-to-end solutions from diagnosis to therapy. Dante’s program began with a focus on rare disease, in response to a diagnosis of a patient with a rare disease for which there were no treatment therapies. Dante’s pipeline has evolved across multiple disease areas with four drug programs in full internal development and two in co-development to achieve validation and partner externally on clinical trials and commercialization. “Personalized medicine needs personalized data, a